Xeloda () vs Margenza (margetuximab-cmkb)
Xeloda () vs Margenza (margetuximab-cmkb)
Xeloda (capecitabine) is an oral chemotherapy drug that is commonly used to treat certain types of breast cancer and colorectal cancer by interfering with the DNA production in cancer cells, leading to cell death. Margenza (margetuximab-cmkb), on the other hand, is a monoclonal antibody given through intravenous infusion and is specifically indicated for the treatment of patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease. When deciding between Xeloda and Margenza, it is crucial to consider the specific type and progression of cancer, previous treatments, and the molecular characteristics of the tumor, as these factors will determine the appropriateness and potential effectiveness of each medication.
Difference between Xeloda and Margenza
Metric | Xeloda () | Margenza (margetuximab-cmkb) |
---|---|---|
Generic name | Capecitabine | Margetuximab-cmkb |
Indications | Colorectal cancer, metastatic breast cancer | Metastatic HER2-positive breast cancer |
Mechanism of action | Antimetabolite (fluoropyrimidine), thymidine phosphorylase activation | Anti-HER2 monoclonal antibody, immune system modulation |
Brand names | Xeloda | Margenza |
Administrative route | Oral | Intravenous |
Side effects | Hand-foot syndrome, diarrhea, nausea, fatigue | Infusion-related reactions, fatigue, nausea, diarrhea |
Contraindications | Severe renal impairment, DPD deficiency | None known |
Drug class | Antimetabolite, Chemotherapeutic agent | Monoclonal antibody, Antineoplastic agent |
Manufacturer | Hoffmann-La Roche | MacroGenics, Inc. |
Efficacy
Xeloda (Capecitabine) in Breast Cancer Treatment
Xeloda, also known by its generic name capecitabine, is an oral chemotherapy drug that is used to treat breast cancer. It is a prodrug that is metabolized in the body to 5-fluorouracil (5-FU), a substance that interferes with the DNA synthesis of cancer cells, thereby inhibiting their growth and proliferation. Xeloda is particularly effective in the treatment of metastatic breast cancer, especially after failure of anthracycline-containing chemotherapy. The efficacy of Xeloda in breast cancer has been demonstrated in several clinical trials, where it has shown to prolong progression-free survival and, in some cases, overall survival in patients with advanced stages of the disease.
Margenza (Margetuximab-cmkb) in Breast Cancer Treatment
Margenza, with the generic name margetuximab-cmkb, is a monoclonal antibody designed to target the HER2/neu receptor, which is overexpressed in certain types of breast cancer. It is used in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease. Margenza works by binding to the HER2 receptors on cancer cells, thereby inhibiting their growth and survival. The efficacy of Margenza in breast cancer was established in a pivotal phase III clinical trial, which demonstrated an improvement in progression-free survival when compared to trastuzumab, another anti-HER2 therapy, in combination with chemotherapy.
Comparative Efficacy in Clinical Settings
When comparing the efficacy of Xeloda and Margenza, it is important to consider that they are used in different settings and lines of therapy for breast cancer. Xeloda is often used as a single agent for metastatic disease after other treatments have failed, while Margenza is used in combination with chemotherapy in patients who have previously been treated with other anti-HER2 therapies. The choice between these two drugs would depend on the specific characteristics of the breast cancer, such as HER2 receptor status, prior treatments, and the overall condition of the patient.
Conclusion on Efficacy
In conclusion, both Xeloda and Margenza have shown efficacy in the treatment of breast cancer, albeit in different contexts and patient populations. Xeloda is effective in prolonging survival in metastatic breast cancer as a chemotherapeutic agent, while Margenza offers a targeted approach for HER2-positive breast cancer in combination with chemotherapy. The use of these medications should be guided by a healthcare professional, taking into account the individual patient's disease characteristics and treatment history.
Regulatory Agency Approvals
Xeloda
Margenza
Access Xeloda or Margenza today
If Xeloda or Margenza are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us